Aldeyra Therapeutics Inc. is focused on developing innovative medications aimed at treating immune-mediated and metabolic diseases. Their approach emphasizes the modulation of immunological systems rather than the direct inhibition or activation of single protein targets. This strategy aims to optimize multiple biological pathways simultaneously while minimizing potential toxicity. The company is advancing a portfolio of product candidates, including investigational therapies that are currently in late-stage clinical trials, with the goal of addressing unmet medical needs in conditions such as dry eye disease and allergic conjunctivitis.

Among their key product candidates is Reproxalap, an ophthalmic solution designed to treat dry eye disease and allergic conjunctivitis. This novel Reactive Aldehyde Species (RASP) inhibitor has shown promise in clinical trials, demonstrating rapid improvement in symptoms associated with these conditions. Additionally, Aldeyra is exploring other therapeutic candidates, such as ADX-629 for moderate alcoholic hepatitis and Sjögren-Larsson syndrome, and ADX-248 for atopic dermatitis, among others. The company’s commitment to advancing next-generation medicines reflects its mission to enhance patient well-being by filling gaps left by existing treatments.

United States

Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.

Eye Diseases

Inflammatory disorders

Metabolic Diseases

Skin Diseases

Aldeyra Therapeutics Inc.

Dry eye syndrome

RASP effect inflammation signaling via covalent binding to proteins, including receptors and enzymes.
RASP-protein adducts directly influence the function of proteins, leading to activation of intracellular inflammatory factors, including NF-kB, an important mediator in the inflammatory response.
In addition, RASP-protein adducts bind to Scavenger Receptor A, which also initiates pro-inflammatory signaling and leads to the formation of antibodies against the adducted protein, at least in part explaining the presence of host-directed antibodies in autoimmune diseases such as rheumatoid arthritis

Reproxalap (ADX-102)

Allergic conjunctivitis

Rare diseases

Rare genetic disease

RASP effect inflammation signaling via covalent binding to proteins, including receptors and enzymes.
RASP-protein adducts directly influence the function of proteins, leading to activation of intracellular inflammatory factors, including NF-kB, an important mediator in the inflammatory response.
In addition, RASP-protein adducts bind to Scavenger Receptor A, which also initiates pro-inflammatory signaling and leads to the formation of antibodies against the adducted protein, at least in part explaining the presence of host-directed antibodies in autoimmune diseases such as rheumatoid arthritis
(<a href="https://www.aldeyra.com/science-technology/rasp-inhibition/">Source)</a>

Alcoholic hepatitis

Liver disease

ADX-629, an investigational new drug, is a novel, orally administered RASP (reactive aldehyde species) modulator for the potential treatment of systemic immune-mediated diseases. RASP modulators potentially represent upstream immunological switches that shift immune systems from pro-inflammatory states to anti-inflammatory states. ADX-629 is a member of the same chemical class as reproxalap, an investigational new drug in late-stage development for dry eye disease and allergic conjunctivitis, two common ocular inflammatory diseases.
RASP effect inflammation signaling via covalent binding to proteins, including receptors and enzymes.
RASP-protein adducts directly influence the function of proteins, leading to activation of intracellular inflammatory factors, including NF-kB, an important mediator in the inflammatory response.
In addition, RASP-protein adducts bind to Scavenger Receptor A, which also initiates pro-inflammatory signaling and leads to the formation of antibodies against the adducted protein, at least in part explaining the presence of host-directed antibodies in autoimmune diseases such as rheumatoid arthritis

ADX-629 

Sjögren-Larsson Syndrome

ADX-629

Atopic dermatitis

Eye disease

Retinitis Pigmentosa

Dihydrofolate reductase (DHFR) is an enzyme involved in cellular replication and activation. Methotrexate, the active component of ADX-2191, is a DHFR inhibitor, which has been used to treat cancer and autoimmune disease. The anti-proliferative and anti-inflammatory properties of DHFR inhibition are well described.
Proliferative vitreoretinopathy (PVR) is characterized by excessive replication and pro-inflammatory activity of retinal cells, at least a portion of which synthesize collagen, the principal component of scar tissue. Retinal scarring can lead to impairment of vision, including blindness. In preclinical studies of primary cell cultures from PVR patients, DHFR inhibition reduced pathological cell proliferation and scar-like collagen deposition. The observed clinical activity of our investigational new drug ADX-2191 in PVR is believed to be the result of the down-regulation of aberrant retinal cell proliferation and activity, thereby leading to reduced retinal scarring.
<a href="https://www.aldeyra.com/science-technology/dihydrofolate-reductase-inhibition/">Source</a>&nbsp;

ADX-2191

Skin disease/disorder

Analog of ADX-629, ADX-246

ADX-246

Age-related macular degeneration

Geographic atrophy

ADX-248 is an intravitreally administered RASP modulator in development for the treatment of immune-mediated diseases of the retina, including the dry form of age-related macular degeneration, geographic atrophy, and related diseases. ADX-248 is expected to initiate clinical testing in 2024.

Aldeyra Therapeutics Inc.

Company Details